12 research outputs found

    Effect of Static Posture on Online Performance of P300-Based BCIs for TV Control

    Get PDF
    To implement a practical brain-computer interface (BCI) for daily use, continuing changes in postures while performing daily tasks must be considered in the design of BCIs. To examine whether the performance of a BCI could depend on postures, we compared the online performance of P300-based BCIs built to select TV channels when subjects took sitting, recline, supine, and right lateral recumbent postures during BCI use. Subjects self-reported the degrees of interference, comfort, and familiarity after BCI control in each posture. We found no significant difference in the BCI performance as well as the amplitude and latency of P300 and N200 among the four postures. However, when we compared BCI accuracy outcomes normalized within individuals between two cases where subjects reported relatively more positively or more negatively about using the BCI in a particular posture, we found higher BCI accuracy in those postures for which individual subjects reported more positively. As a result, although the change of postures did not affect the overall performance of P300-based BCIs, the BCI performance varied depending on the degree of postural comfort felt by individual subjects. Our results suggest considering the postural comfort felt by individual BCI users when using a P300-based BCI at home

    Effects of Emotional Stimulations on the Online Operation of a P300-Based Brain-Computer Interface

    Get PDF
    Using P300-based brain-computer interfaces (BCIs) in daily life should take into account the user's emotional state because various emotional conditions are likely to influence event-related potentials (ERPs) and consequently the performance of P300-based BCIs. This study aimed at investigating whether external emotional stimuli affect the performance of a P300-based BCI, particularly built for controlling home appliances. We presented a set of emotional auditory stimuli to subjects, which had been selected for each subject based on individual valence scores evaluated a priori, while they were controlling an electric light device using a P300-based BCI. There were four conditions regarding the auditory stimuli, including high valence, low valence, noise, and no sound. As a result, subjects controlled the electric light device using the BCI in real time with a mean accuracy of 88.14%. The overall accuracy and P300 features over most EEG channels did not show a significant difference between the four auditory conditions (p > 0.05). When we measured emotional states using frontal alpha asymmetry (FAA) and compared FAA across the auditory conditions, we also found no significant difference (p > 0.05). Our results suggest that there is no clear evidence to support a hypothesis that external emotional stimuli influence the P300-based BCI performance or the P300 features while people are controlling devices using the BCI in real time. This study may provide useful information for those who are concerned with the implementation of a P300-based BCI in practice

    Use of Brain-Computer Interfaces in Different Postures for Daily Living Applications

    No full text

    Comparisons of Auditory, Audiovisual, and Visual Modalities in Feature Domain for Auditory Brain-Computer Interfaces

    No full text
    The development of non-visual P300-based brain-computer interfaces (BCIs) is needed for patients with unreliable gaze control or healthy users with visual distractors. As an alternative means, auditory BCIs have been developed, but reportedly showed relatively low performance. To elucidate the performance gap, this study investigated the feature domain between the auditory and visual BCIs, along with the audiovisual BCI as the combination of the two. Not only the online test, but also a cross-modality assessment was conducted to compare the performance of three modalities, revealing that the classification performance became significantly low when the feature of the auditory BCI was included. When comparing the features that showed significant differences between the target and nontarget stimuli of each subject in each modality, significant individual differences in selected features were more pronounced in the auditory BCI than others, meaning that the common features across subjects were scarce for the auditory BCI. Moreover, the biggest decrease was shown in the auditory modality when comparing the performance of online test and Leave-One-Subject-Out (LOSO) cross validation, which was conducted with selected features. Our results suggest potential sources of the performance gap between auditory and visual BCIs in the context of feature domain

    Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center

    No full text
    Biologics are important treatment options for psoriasis; however, direct comparison of their efficacy, safety, and drug survival is insufficient in clinical practice. This retrospective single-center study aimed to compare the efficacy, safety, and drug survival of three commonly used psoriasis biologics (secukinumab, ustekinumab, and guselkumab) and identify the factors affecting drug survival in actual clinics in Korea. We enrolled 111 patients with moderate to severe psoriasis and for at least 56 weeks of follow-up; among these, 27, 23, and 61 were administered secukinumab, ustekinumab, and guselkumab, respectively. All groups were comparable with respect to their baseline characteristics. Secukinumab showed a rapid response, and guselkumab was superior in terms of a long-term response and complete remission compared with other biologics, while ustekinumab showed a lower efficacy compared with other biologics. All three biologics had a favorable and similar safety profile; however, allergic reactions and latent tuberculosis were more common with secukinumab and ustekinumab, respectively. Guselkumab was the most sustained biologic, and the survival rates of secukinumab and ustekinumab were similar. Drug survival was remarkably shorter in female patients and those with hypertension. Introduction of new biologics emerged as a negative factor for drug survival in clinical settings
    corecore